Y. Pommier, Topoisomerase I inhibitors: camptothecins and beyond, Nature Reviews Cancer, vol.24, issue.10, pp.789-802, 2006.
DOI : 10.1038/nrc1977

J. Han, H. Lim, E. Shin, Y. Yoo, Y. Park et al., Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non???Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin, Journal of Clinical Oncology, vol.24, issue.15, pp.2237-2281, 2006.
DOI : 10.1200/JCO.2005.03.0239

N. Boku, S. Yamamoto, H. Fukuda, K. Shirao, T. Doi et al., Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study, The Lancet Oncology, vol.10, issue.11, pp.1063-1072, 2009.
DOI : 10.1016/S1470-2045(09)70259-1

R. Hertzberg, M. Caranfa, and S. Hecht, On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex, Biochemistry, vol.28, issue.11, pp.4629-4667, 1989.
DOI : 10.1021/bi00437a018

J. Tsurutani, T. Nitta, T. Hirashima, T. Komiya, H. Uejima et al., Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan, Lung Cancer, vol.35, issue.3, pp.299-304, 2002.
DOI : 10.1016/S0169-5002(01)00425-1

C. Gongora, N. Vezzio-vie, S. Tuduri, V. Denis, A. Causse et al., New Topoisomerase I mutations are associated with resistance to camptothecin, Molecular Cancer, vol.10, issue.1, p.64, 2011.
DOI : 10.1016/j.jmb.2004.03.077

URL : https://hal.archives-ouvertes.fr/inserm-00602236

L. Doyle, W. Yang, L. Abruzzo, T. Krogmann, Y. Gao et al., A multidrug resistance transporter from human MCF-7 breast cancer cells, Proceedings of the National Academy of Sciences, vol.95, issue.26, pp.15665-70, 1998.
DOI : 10.1073/pnas.95.26.15665

J. Han, H. Lim, Y. Yoo, E. Shin, Y. Park et al., Associations ofABCB1, ABCC2, andABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer, Cancer, vol.10, issue.1, pp.138-185, 2007.
DOI : 10.1002/cncr.22760

L. Candeil, I. Gourdier, D. Peyron, N. Vezzio, V. Copois et al., ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases, International Journal of Cancer, vol.63, issue.6, pp.848-54, 2004.
DOI : 10.1002/ijc.20032

C. Yang, E. Schneider, M. Kuo, E. Volk, E. Rocchi et al., BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells, Biochemical Pharmacology, vol.60, issue.6, pp.831-838, 2000.
DOI : 10.1016/S0006-2952(00)00396-8

K. Nakatomi, M. Yoshikawa, M. Oka, Y. Ikegami, S. Hayasaka et al., Transport of 7-Ethyl-10-hydroxycamptothecin (SN-38) by Breast Cancer Resistance Protein ABCG2 in Human Lung Cancer Cells, Biochemical and Biophysical Research Communications, vol.288, issue.4, pp.827-859, 2001.
DOI : 10.1006/bbrc.2001.5850

E. Volk and E. Schneider, Wild-type breast cancer resistance protein (BCRP/ ABCG2) is a methotrexate polyglutamate transporter, Cancer Res, vol.63, pp.5538-5581, 2003.

Y. Honjo, C. Hrycyna, Q. Yan, W. Medina-perez, R. Robey et al., Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells, Cancer Res, vol.61, pp.6635-6644, 2001.

C. Ozvegy-laczka, T. Hegedus, G. Varady, O. Ujhelly, J. Schuetz et al., High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter, Molecular Pharmacology, vol.65, issue.6, pp.1485-95, 2004.
DOI : 10.1124/mol.65.6.1485

C. Hegedus, C. Ozvegy-laczka, A. Apati, M. Magocsi, K. Nemet et al., Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties, British Journal of Pharmacology, vol.7, issue.4
DOI : 10.1111/j.1476-5381.2009.00383.x

F. Li, Anticancer drug FL118 is more than a survivin inhibitor: Where is the Achilles' heel of cancer?, Am J Cancer Res, vol.4, pp.304-315, 2014.

X. Ling, S. Cao, Q. Cheng, J. Keefe, Y. Rustum et al., A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity, PLoS ONE, vol.7, issue.9, p.45571, 2012.
DOI : 10.1371/journal.pone.0045571.t002

R. Wadkins, D. Bearss, G. Manikumar, M. Wani, M. Wall et al., Hydrophilic Camptothecin Analogs That Form Extremely Stable Cleavable Complexes with DNA and Topoisomerase I, Cancer Research, vol.64, issue.18, pp.6679-83, 2004.
DOI : 10.1158/0008-5472.CAN-04-1885

A. Knab, J. Fertala, and M. Bjornsti, A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons, J Biol Chem, vol.270, pp.6141-6149, 1995.

J. Zhao, X. Ling, S. Cao, X. Liu, S. Wan et al., Antitumor Activity of FL118, a Survivin, Mcl-1, XIAP, and cIAP2 Selective Inhibitor, Is Highly Dependent on Its Primary Structure and Steric Configuration, Molecular Pharmaceutics, vol.11, issue.2, pp.457-67, 2014.
DOI : 10.1021/mp4004282

X. Ling, C. Xu, C. Fan, K. Zhong, F. Li et al., FL118 Induces p53-Dependent Senescence in Colorectal Cancer Cells by Promoting Degradation of MdmX, Cancer Research, vol.74, issue.24, pp.7487-97, 2014.
DOI : 10.1158/0008-5472.CAN-14-0683

K. Shiozawa, M. Oka, H. Soda, M. Yoshikawa, Y. Ikegami et al., Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic, International Journal of Cancer, vol.96, issue.1, pp.146-51, 2004.
DOI : 10.1002/ijc.11528

J. Allen, A. Van-loevezijn, J. Lakhai, M. Van-der-valk, O. Van-tellingen et al., Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C, Mol Cancer Ther, vol.1, pp.417-442, 2002.

S. Dallavalle, T. Delsoldato, A. Ferrari, L. Merlini, S. Penco et al., Novel 7-Substituted Camptothecins with Potent Antitumor Activity, Journal of Medicinal Chemistry, vol.43, issue.21, pp.3963-3972, 2000.
DOI : 10.1021/jm000944z

D. Meco, D. Francesco, A. Cusano, G. Bucci, F. Pierri et al., Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models, Cancer Chemotherapy and Pharmacology, vol.54, issue.6, pp.811-833, 2012.
DOI : 10.1007/s00280-012-1973-0

R. Rajendra, M. Gounder, A. Saleem, J. Schellens, D. Ross et al., Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9- nitrocamptothecin, Cancer Res, vol.63, pp.3228-3261, 2003.

M. Yoshikawa, Y. Ikegami, S. Hayasaka, K. Ishii, A. Ito et al., Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells, International Journal of Cancer, vol.47, issue.6, pp.921-928, 2004.
DOI : 10.1002/ijc.20216

X. Ling and F. Li, An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI), Am J Transl Res, vol.5, pp.139-54, 2013.

M. Galsky, A. Dritselis, P. Kirkpatrick, W. Oh, and . Cabazitaxel, Cabazitaxel, Nature Reviews Drug Discovery, vol.363, issue.9, pp.677-685, 2010.
DOI : 10.1038/nrd3254

S. Sawada, K. Nokata, T. Furuta, T. Yokokura, and T. Miyasaka, Chemical Modification of an Antitumor Alkaloid Camptothecin: Synthesis and Antitumor Activity of 7-C-Substituted Camptothecins., CHEMICAL & PHARMACEUTICAL BULLETIN, vol.39, issue.10, pp.2574-80, 1991.
DOI : 10.1248/cpb.39.2574

D. Adams, D. Silva, M. Flowers, J. Kohlhagen, G. Pommier et al., Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex, Cancer Chemotherapy and Pharmacology, vol.37, issue.2, pp.135-179, 2006.
DOI : 10.1007/s00280-005-0007-6

M. Ho, T. Bera, M. Willingham, M. Onda, R. Hassan et al., Mesothelin Expression in Human Lung Cancer, Clinical Cancer Research, vol.13, issue.5, pp.1571-1576, 2007.
DOI : 10.1158/1078-0432.CCR-06-2161

X. Ling, R. Bernacki, M. Brattain, and F. Li, Induction of Survivin Expression by Taxol (Paclitaxel) Is an Early Event, Which Is Independent of Taxol-mediated G2/M Arrest, Journal of Biological Chemistry, vol.279, issue.15, pp.15196-203, 2004.
DOI : 10.1074/jbc.M310947200

S. Jo, M. Vargyas, J. Vasko-szedlar, B. Roux, and W. Im, PBEQ-Solver for online visualization of electrostatic potential of biomolecules, Nucleic Acids Research, vol.36, issue.Web Server, pp.270-275, 2008.
DOI : 10.1093/nar/gkn314

S. Jo, T. Kim, V. Iyer, and W. Im, CHARMM-GUI: A web-based graphical user interface for CHARMM, Journal of Computational Chemistry, vol.89, issue.11, pp.1859-65, 2008.
DOI : 10.1002/jcc.20945

J. Huheey, The Electronegativity of Groups, The Journal of Physical Chemistry, vol.69, issue.10, pp.3284-91, 1965.
DOI : 10.1021/j100894a011

J. Huheey, The Electronegativity of Multiply Bonded Groups, The Journal of Physical Chemistry, vol.70, issue.7, pp.2086-92, 1966.
DOI : 10.1021/j100879a003

N. Inamoto and S. Masuda, REVISED METHOD FOR CALCULATION OF GROUP ELECTRONEGATIVITIES, Chemistry Letters, vol.11, issue.7, pp.1003-1009, 1982.
DOI : 10.1246/cl.1982.1003

H. Wu, Chemical Property Calculation through JavaScript and Applications in QSAR, Molecules, vol.4, issue.1, pp.16-27, 1999.
DOI : 10.3390/40100016

R. Goldberg, D. Sargent, R. Morton, C. Fuchs, R. Ramanathan et al., A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.22, issue.1, pp.23-30, 2004.
DOI : 10.1200/JCO.2004.09.046

A. Schmittel, M. Sebastian, F. Von-weikersthal, L. Martus, P. Gauler et al., A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer, Annals of Oncology, vol.22, issue.8, pp.1798-804, 2011.
DOI : 10.1093/annonc/mdq652